Greenland Mines Ltd GRML
Mines"), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases –
cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio
and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which
uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $634.2K | $0 | $0 | — | — |
| SG&A | $3.1M | $2.8M | $30.5K | $534.0K | — |
| Total operating expenses | $7.1M | $5.5M | $631.3K | $153.1K | — |
| Operating income | -$7.1M | -$5.5M | -$631.3K | -$657.0K | — |
| Interest expense | $2.3M | $356.6K | $76.2K | — | — |
| Pre-tax income | -$10.6M | -$6.2M | -$707.5K | $1.6M | — |
| Income tax | — | — | $690.6K | $322.0K | — |
| Net income | -$10.6M | -$6.2M | -$707.5K | $1.2M | — |
| EPS, basic | -0.22 | -0.32 | -0.05 | — | — |
| EPS, diluted | -0.22 | -0.32 | -0.05 | — | — |
| Shares, diluted (wtd. avg.) | $48.5M | $19.2M | $15.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $7.2M | $63.7K | $2.8K | $75.9K | $5.0K |
| Total current assets | $7.3M | $157.8K | $6.6K | $440.2K | $5.0K |
| Total assets | $9.6M | $2.5M | $2.2M | $118.2M | $5.0K |
| Accounts payable | $44.6K | $63.7K | $151.3K | — | — |
| Short-term debt | — | — | — | $300.0K | — |
| Total current liabilities | $76.8K | $1.2M | $1.6M | $506.2K | $8.5K |
| Total liabilities | $129.8K | $1.3M | $1.6M | $4.9M | $8.5K |
| Retained earnings | -$21.1M | -$10.6M | -$3.9M | -$4.0M | -$3.6K |
| Total equity | $9.5M | $1.2M | -$442.7K | -$4.0M | -$3.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$2.9M | -$446.9K | -$493.0K | — |
| Stock-based compensation | $1.6M | $2.6M | — | — | — |
| Investing cash flow | — | -$123.5K | $23.9K | -$116.2M | — |
| Financing cash flow | $13.0M | $3.1M | $350.0K | $117.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-090213.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |